Polscope Analysis of Meiotic Spindle and Zona Pellucida Birefringence of Metaphase II Oocytes in Polycystic Ovarian Syndrome Patients

International Journal of Fertility & Sterility

دوره 9 - شماره Suppl.1

Article Type: Original Article
Abstract:
Background: Polycystic ovarian syndrome (PCOs) is one of the most common causes of infertility in women of reproductive age. Currently, one of the best therapeutic options for PCOs patients is ICSI. Moreover, IVM can be a useful technique for women with PCOs who are at the risk of ovarian hyperstimulation syndrome (OHSS). On the other hand, the oocyte quality can be a determining factor for outcome of ICSI cycles. The goal was to compare both zona pellucida (ZP) birefringence and meiotic spindle (MS) of the in-vivo with in vitro-matured oocytes from PCOs patients using noninvasive PolScope system.re Materials and methods: This prospective study included immature oocytes (30 GV and 5 MI) undergoing IVM, and MII oocytes obtained from PCOs patients (mean age SD, 29.64  5.31 years) in ICSI program. Using a PolScope, the presence of MS and ZP birefringences were assessed in both in vivo-matured (n=32) and matured oocytes after IVM (n=24). Oocytes were classified as high birefringent (HB) ZP and low birefringent (LB) ZP. Furthermore, the rates of fertilization and embryo development were evaluated. Results: The oocyte maturation rate was 68.5% after IVM. Analysis revealed that the percentage of a HB ZP was significantly higher in the IVM oocytes than in vivo-matured ones (58.3 vs. 31.2%, P=0.04). There was insignificant relationship between MS detection and either in vivo-maturation or IVM oocytes (P=0.53). Likewise, there were similar outcomes for the rates of fertilization and embryo development after ICSI between two groups, respectively (P=0.80 and P=0.13,).9 Conclusion: Clinical IVM is a safe technology for the maturation and maintenance of oocytes integrity in PCOs patients. Furthermore, the non-invasive PolScope could be used to select healthy oocytes for insemination in ICSI patients with immature oocytes after retrieval.